SRR8613749
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- ADIPOGENESIS+0.290
- MTORC1_SIGNALING+0.290
- CHOLESTEROL_HOMEOSTASIS+0.280
- GLYCOLYSIS+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.250
- FATTY_ACID_METABOLISM+0.230
- SPERMATOGENESIS+0.230
- UV_RESPONSE_UP+0.230
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- INFLAMMATORY_RESPONSE-0.410
- UV_RESPONSE_DN-0.350
- ANGIOGENESIS-0.330
- TNFA_SIGNALING_VIA_NFKB-0.320
- COMPLEMENT-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ccfdc2a2-bb01-41c2-9ef1-98bbd1cfae22 | — | — | 0.889 |
| 2 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.858 |
| 3 | TCGA-CV-6962-01A-11R-1915-07 | — | — | 0.846 |
| 4 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.845 |
| 5 | TCGA-33-AASB-01A-11R-A405-07 | — | cohortA4 | 0.842 |
| 6 | TCGA-B6-A0IB-01A-11R-A034-07 | — | B | 0.836 |
| 7 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.834 |
| 8 | SRR2669446 | — | — | 0.831 |
| 9 | MBCProject_0108_T2_RNA | — | B | 0.830 |
| 10 | s0112311 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |